Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of anifrolumab in Asian patients with active systemic lupus erythematosus
CTR20211707Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Nov 2021; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20211707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211707.